I know, Taurean. :) I'm aware of the differentiation between...

I know, Taurean. I'm aware of the differentiation between Lyramid and Kinera and had pointed it out before in other research related posts.

I was addressing pharmageddon, who was asking where to place this study in the context of the ischemic programs. I thought he was referring to my quote "MK is detrimental to cardiac function". In the context of developing a heart attack drug where the therapeutic agent is MK that may sound confusing. So my point was that even in the isolated context of heart diseases there may be different therapeutic approaches for different indications.

In hindsight though, pharma may just have been asking a more general question than that. Anyway, it's always good to clarify. I'll try to be clearer next time.